Efficacy of Daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation.

Antimicrobial Agents and Chemotherapy
Henry S HeineW Russell Byrne

Abstract

Daptomycin demonstrated in vitro (MIC(90), 4 μg/ml) and in vivo activities against Bacillus anthracis. Twice-daily treatment with a dose of 50 mg/kg of body weight was begun 24 h after challenge and continued for 14 or 21 days; results were compared to those for controls treated with phosphate-buffered saline or ciprofloxacin. Day 43 survival rates were 6/10 mice for the 14-day and 9/10 mice for the 21-day treatment groups, compared to survival with ciprofloxacin: 8/10 and 9/10 mice, respectively. Culture results from tissues removed at the termination of the experiment were negative.

References

Jan 1, 1991·Scandinavian Journal of Infectious Diseases·M Doğanay, N Aydin
May 1, 1993·The Journal of Infectious Diseases·A M FriedlanderP Mikesell
Mar 21, 1998·Archives of Internal Medicine·J C PileA M Friedlander
Jul 15, 2000·Antimicrobial Agents and Chemotherapy·C H ChoeG B Knudson
Nov 9, 2001·MMWR. Morbidity and Mortality Weekly Report·UNKNOWN Centers for Disease Control and Prevention (CDC)
Dec 12, 2001·International Journal of Antimicrobial Agents·I BrookG B Knudson
Mar 9, 2002·Science·Ron Brookmeyer, Natalie Blades
May 1, 2002·JAMA : the Journal of the American Medical Association·Thomas V InglesbyUNKNOWN Working Group on Civilian Biodefense
Mar 26, 2003·Antimicrobial Agents and Chemotherapy·Barry H DvorchikRobert D Arbeit
Jul 25, 2003·Antimicrobial Agents and Chemotherapy·Jared A SilvermanHoward M Shapiro
Sep 1, 1955·A.M.A. Archives of Internal Medicine·H GOLD
Dec 25, 2003·Antimicrobial Agents and Chemotherapy·Nasia SafdarW A Craig
Feb 14, 2007·Antimicrobial Agents and Chemotherapy·Henry S HeineW Russell Byrne

❮ Previous
Next ❯

Citations

May 1, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Peter E PertelJeff Alder
Jun 29, 2011·Antimicrobial Agents and Chemotherapy·Anna-Barbara HachmannJohn D Helmann
Jan 1, 2012·Journal of Community Hospital Internal Medicine Perspectives·Amesh A Adalja
Aug 1, 2014·Epidemiology and Infection·D J InverarityJ P Ruddy
Nov 5, 2016·BMC Infectious Diseases·Breanne M HeadAdrienne F A Meyers
Oct 5, 2013·Clinical Microbiology Reviews·Romney M HumphriesGeorge Sakoulas
Jun 15, 2020·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Taylor MorrisetteMichael J Rybak

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.